Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $4.2 million.

  • Zevra Therapeutics' Free Cash Flow rose 12290.39% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.2 million, marking a year-over-year increase of 6520.93%. This contributed to the annual value of -$69.7 million for FY2024, which is 10592.06% down from last year.
  • Zevra Therapeutics' Free Cash Flow amounted to $4.2 million in Q3 2025, which was up 12290.39% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Free Cash Flow registered a high of $16.5 million during Q2 2021, and its lowest value of -$19.1 million during Q2 2024.
  • Its 5-year average for Free Cash Flow is -$6.3 million, with a median of -$4.5 million in 2022.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 65220.76% in 2021, then plummeted by 41976.88% in 2022.
  • Zevra Therapeutics' Free Cash Flow (Quarter) stood at -$865000.0 in 2021, then crashed by 419.77% to -$4.5 million in 2022, then crashed by 260.99% to -$16.2 million in 2023, then fell by 0.12% to -$16.2 million in 2024, then soared by 125.57% to $4.2 million in 2025.
  • Its Free Cash Flow was $4.2 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$8.3 million in Q1 2025.